HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer

Molecular Oncology

Volumn 9, Issue 3, 2015, Pages 586-600

  Boulbes, Delphine R ^a   Arold, Stefan T ^a,e   Chauhan, Gaurav B ^a   Blachno, Korina V ^a   Deng, Nanfu ^a   Chang, Wei Chao ^b   Jin, Quanri ^a   Huang, Tzu Hsuan ^a   Hsu, Jung Mao ^a   Brady, Samuel W ^a   Bartholomeusz, Chandra ^a   Ladbury, John E ^a,f   Stone, Steve ^c   Yu, Dihua ^a   Hung, Mien Chie ^a   Esteva, Francisco J ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Utah   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

^f UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Biomarker; Drug resistance; HER family mutation; Kinase domain; Lapatinib; TKI

Indexed keywords

CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN; LAPATINIB; TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; QUINAZOLINE DERIVATIVE;

ANIMAL MODEL; ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CELL INVASION ASSAY; CELL LYSATE; CELL MUTANT; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; ENZYME ASSAY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SITE DIRECTED MUTAGENESIS; TREATMENT RESPONSE; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BIOLOGY; BREAST NEOPLASMS; CHEMISTRY; DISEASE COURSE; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; PROGNOSIS; PROTEIN TERTIARY STRUCTURE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DISEASE PROGRESSION; ERBB RECEPTORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MICE, NUDE; MUTANT PROTEINS; MUTATION; PHENOTYPE; PHOSPHORYLATION; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84923373832     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.10.011     Document Type: Article

References (61)

1. Arnold K., Bordoli L., Kopp J., Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006, 22:195-201.
2. Babchia N., Calipel A., Mouriaux F., Faussat A.M., Mascarelli F. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines. Invest. Ophthalmol. Vis. Sci. 2008, 49:2348-2356.
3. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006, 312:1175-1178.
4. Baselga J., Cortes J., Kim S.B., Im S.A., Hegg R., Im Y.H., Roman L., Pedrini J.L., Pienkowski T., Knott A., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N.Engl. J. Med. 2012, 366:109-119.
5. Bose R., Kavuri S.M., Searleman A.C., Shen W., Shen D., Koboldt D.C., Monsey J., Goel N., Aronson A.B., Li S., et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013, 1-15. online first.
6. Boulbes D.R., Shaiken T., Sarbassov dos D. Endoplasmic reticulum is a main localization site of mTORC2. Biochem. Biophys. Res. Commun. 2011, 413:46-52.
7. Brennan P.J., Kumagai T., Berezov A., Murali R., Greene M.I. HER2/neu: mechanisms of dimerization/oligomerization. Oncogene 2000, 19:6093-6101.
8. Breyer J.P., Sanders M.E., Airey D.C., Cai Q., Yaspan B.L., Schuyler P.A., Dai Q., Boulos F., Olivares M.G., Bradley K.M., et al. Heritable variation of ERBB2 and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 2009, 18:1252-1258.
9. Citri A., Gan J., Mosesson Y., Vereb G., Szollosi J., Yarden Y. Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep. 2004, 5:1165-1170.
10. Deb T.B., Su L., Wong L., Bonvini E., Wells A., David M., Johnson G.R. Epidermal growth factor (EGF) receptor kinase-independent signaling by EGF. J.Biol. Chem. 2001, 276:15554-15560.
11. Debnath J., Muthuswamy S.K., Brugge J.S. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003, 30:256-268.
12. Esteva F.J., Guo H., Zhang S., Santa-Maria C., Stone S., Lanchbury J.S., Sahin A.A., Hortobagyi G.N., Yu D. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am. J. Pathol. 2010, 177:1647-1656.
13. Esteva F.J., Yu D., Hung M.C., Hortobagyi G.N. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat. Rev. Clin. Oncol. 2010, 7:98-107.
14. Frank B., Hemminki K., Wirtenberger M., Bermejo J.L., Bugert P., Klaes R., Schmutzler R.K., Wappenschmidt B., Bartram C.R., Burwinkel B. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis 2005, 26:643-647.
15. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Kofler M., Jorissen R.N., Nice E.C., Burgess A.W., Ward C.W. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 2003, 11:495-505.
16. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., Jagiello-Gruszfeld A., Crown J., Chan A., Kaufman B., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N.Engl. J. Med. 2006, 355:2733-2743.
17. Ghosh R., Narasanna A., Wang S.E., Liu S., Chakrabarty A., Balko J.M., Gonzalez-Angulo A.M., Mills G.B., Penuel E., Winslow J., et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011, 71:1871-1882.
18. Gotoh N., Tojo A., Hino M., Yazaki Y., Shibuya M. A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor. Biochem. Biophys. Res. Commun. 1992, 186:768-774.
19. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997, 16:1647-1655.
20. Hazan R., Margolis B., Dombalagian M., Ullrich A., Zilberstein A., Schlessinger J. Identification of autophosphorylation sites of HER2/neu. Cell Growth Differ. 1990, 1:3-7.
21. Herter-Sprie G.S., Greulich H., Wong K.K. Activating mutations in ERBB2 and their impact on diagnostics and treatment. Front. Oncol. 2013, 3:86.
22. Huang X., Gao L., Wang S., McManaman J.L., Thor A.D., Yang X., Esteva F.J., Liu B. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res. 2010, 70:1204-1214.
23. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5:341-354.
24. Hynes N.E., Stern D.F. The biology of erbb-2/neu/her-2 and its role in cancer. Biochim. Biophys. Acta 1994, 1198:165-184.
25. Jin Q., Yuan L.X., Boulbes D., Baek J.M., Wang Y.N., Gomez-Cabello D., Hawke D.H., Yeung S.C., Lee M.H., Hortobagyi G.N., et al. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res. 2010, 12:R96.
26. Junttila T.T., Akita R.W., Parsons K., Fields C., Lewis Phillips G.D., Friedman L.S., Sampath D., Sliwkowski M.X. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440.
27. Koboldt D.C., Fulton R.S., McLellan M.D., Schmidt H., Kalicki-Veizer J., McMichael J.F., Fulton L.L., Dooling D.J., Ding L., Mardis E.R., et al. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
28. Larson J.S., Goodman L.J., Tan Y., Defazio-Eli L., Paquet A.C., Cook J.W., Rivera A., Frankson K., Bose J., Chen L., et al. Analytical validation of a highly quantitative, sensitive, accurate, and reproducible assay (HERmark) for the measurement of HER2 total protein and HER2 homodimers in FFPE breast cancer tumor specimens. Pathol. Res. Int. 2010, 2010:814176.
29. Lee J.W., Soung Y.H., Seo S.H., Kim S.Y., Park C.H., Wang Y.P., Park K., Nam S.W., Park W.S., Kim S.H., et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin. Cancer Res. 2006, 12:57-61.
30. Lehrer S., Lee P., Tartter P., Shank B., Brower S.T. Breast cancer and family history: a multivariate analysis of levels of tumor HER2 protein and family history of cancer in women who have breast cancer. Mt. Sinai J. Med. 1995, 62:415-418.
31. Liang K., Esteva F.J., Albarracin C., Stemke-Hale K., Lu Y., Bianchini G., Yang C.Y., Li Y., Li X., Chen C.T., et al. Recombinant human erythropoietin antagonizes trastuzumabtreatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 2010, 18:423-435.
32. Lin W.L., Kuo W.H., Chen F.L., Lee M.Y., Ruan A., Tyan Y.S., Hsu J.D., Chiang H., Han C.P. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer. Ann. Surg. Oncol. 2011, 18:2388-2394.
33. Mahlknecht G., Maron R., Mancini M., Schechter B., Sela M., Yarden Y. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc. Natl. Acad. Sci. U S A 2013, 110:8170-8175.
34. Modi S., Stopeck A.T., Gordon M.S., Mendelson D., Solit D.B., Bagatell R., Ma W., Wheler J., Rosen N., Norton L., et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J.Clin. Oncol. 2007, 25:5410-5417.
35. Monsey J., Shen W., Schlesinger P., Bose R. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted invitro system. J.Biol. Chem. 2010, 285:7035-7044.
36. Morrow P.K., Wulf G.M., Ensor J., Booser D.J., Moore J.A., Flores P.R., Xiong Y., Zhang S., Krop I.E., Winer E.P., et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J.Clin. Oncol. 2011, 29:3126-3132.
37. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., Klos K.S., Li P., Monia B.P., Nguyen N.T., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
38. Nahta R., Yuan L.X., Zhang B., Kobayashi R., Esteva F.J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005, 65:11118-11128.
39. Olayioye M.A. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 2001, 3:385-389.
40. Ouyang X., Gulliford T., Epstein R.J. The duration of phorbol-inducible ErbB2 tyrosine dephosphorylation parallels that of receptor endocytosis rather than threonine-686 phosphorylation: implications for the physiological role of protein kinase C in growth factor receptor signalling. Carcinogenesis 1998, 19:2013-2019.
41. Pacey S., Gore M., Chao D., Banerji U., Larkin J., Sarker S., Owen K., Asad Y., Raynaud F., Walton M., et al. A phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest. New Drugs 2012, 30:341-349.
42. Pallis A.G., Voutsina A., Kalikaki A., Souglakos J., Briasoulis E., Murray S., Koutsopoulos A., Tripaki M., Stathopoulos E., Mavroudis D., Georgoulias V. 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br. J. Cancer 2007, 97:1560-1566.
43. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N.Engl. J. Med. 2005, 353:1659-1672.
44. Rafidi H., Mercado F., Astudillo M., Fry W.H., Saldana M., Carraway K.L., Sweeney C. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3). J.Biol. Chem. 2013, 288:21593-21605.
45. Rexer B.N., Ham A.J., Rinehart C., Hill S., Granja-Ingram Nde M., Gonzalez-Angulo A.M., Mills G.B., Dave B., Chang J.C., Liebler D.C., Arteaga C.L. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 2011, 30:4163-4174.
46. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N.Engl. J. Med. 2005, 353:1673-1684.
47. Santarpia L., Qi Y., Stemke-Hale K., Wang B., Young E.J., Booser D.J., Holmes F.A., O'Shaughnessy J., Hellerstedt B., Pippen J., et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res. Treat. 2012 Jul, 134(1):333-343.
48. Scaltriti M., Rojo F., Ocana A., Anido J., Guzman M., Cortes J., Di Cosimo S., Matias-Guiu X., Cajal S., Arribas J., Baselga J. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J.Natl. Cancer Inst. 2007, 99:628-638.
49. Scaltriti M., Serra V., Normant E., Guzman M., Rodriguez O., Lim A.R., Slocum K.L., West K.A., Rodriguez V., Prudkin L., et al. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer. Mol. Cancer Ther. 2011, 10:817-824.
50. Schulz R., Marchenko N.D., Holembowski L., Fingerle-Rowson G., Pesic M., Zender L., Dobbelstein M., Moll U.M. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J.Exp. Med. 2012, 209:275-289.
51. Shan Y., Eastwood M.P., Zhang X., Kim E.T., Arkhipov A., Dror R.O., Jumper J., Kuriyan J., Shaw D.E. Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell 2012, 149:860-870.
52. Shih J.Y., Gow C.H., Yu C.J., Yang C.H., Chang Y.L., Tsai M.F., Hsu Y.C., Chen K.Y., Su W.P., Yang P.C. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced non small cell lung cancer. Int. J. Cancer 2006, 118:963-969.
53. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., Mackey J., Glaspy J., Chan A., Pawlicki M., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N.Engl. J. Med. 2011, 365:1273-1283.
54. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N.Engl. J. Med. 2001, 344:783-792.
55. Solit D.B., Zheng F.Z.F., Drobnjak M., Munster P.N., Higgins B., Verbel D., Heller G., Tong W., Cordon-Cardo C., Agus D.B., et al. 17-allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 2002, 8:986-993.
56. Tikhomirov O., Carpenter G. Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. Cancer Res. 2003, 63:39-43.
57. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., Lorimer I., Zhang T., Liu N., Daneshmand M., et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N.Engl. J. Med. 2005, 353:133-144.
58. Wang S.E., Narasanna A., Perez-Torres M., Xiang B., Wu F.Y., Yang S., Carpenter G., Gazdar A.F., Muthuswamy S.K., Arteaga C.L. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006, 10:25-38.
59. Weber F., Fukino K., Sawada T., Williams N., Sweet K., Brena R.M., Plass C., Caldes T., Mutter G.L., Villalona-Calero M.A., Eng C. Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. Br. J. Cancer 2005, 92:1922-1926.
60. Zhang S., Huang W.C., Li P., Guo H., Poh S.B., Brady S.W., Xiong Y., Tseng L.M., Li S.H., Ding Z., et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med. 2011, 17:461-469.
61. Zhang X., Gureasko J., Shen K., Cole P.A., Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125:1137-1149.